Start a live chat
1-800-870-4800
NMN and NR —
the structural difference
that defines their relationship.
NMN and NR are the two most studied NAD+ precursors in the longevity literature. They are related — NR is one step upstream of NMN in the Salvage Pathway — but they are not interchangeable. Understanding their structural relationship, their different entry points into the pathway, and what the current literature says about each is the clearest way to understand the NAD+ precursor family.
I
Two molecules, one pathway —
and a one-step structural difference.
NMN and NR are not competing molecules in the way that consumer comparisons often frame them. They are sequential members of the same biosynthetic pathway — the Salvage Pathway, the dominant route to NAD+ in adult human tissue. NR sits one enzymatic step upstream of NMN. The enzyme NRK (nicotinamide riboside kinase) converts NR to NMN by adding a phosphate group. NMNAT then converts NMN to NAD+ by adding an AMP group. Both molecules are, ultimately, on their way to the same destination.
The structural difference between them is precisely that phosphate group. NMN is a nucleotide — it has a phosphate attached to its ribose sugar. NR is a nucleoside — it does not. This single structural distinction has downstream consequences for how each molecule interacts with cell membranes, how each enters cells, and at which point in the Salvage Pathway each arrives. It is not a trivial difference, but it is also not the simple "better or worse" distinction that popular comparisons tend to imply.
How NMN and NR each reach the intracellular NAD+ synthesis machinery continues to be characterized in the research literature. Both molecules are absorbed and both raise circulating NAD+ levels in human studies. The precise pharmacokinetics of each — including cellular uptake routes and tissue distribution — represent an area where the science is still developing. What is established is that both molecules arrive at NAD+ through the Salvage Pathway, and that the structural difference between them determines which enzymatic steps each requires along the way.
NMN and NR are not
competing molecules.
They are sequential members
of the same pathway —
separated by one phosphate group
and one enzymatic step.
Side by Side
NMN and NR — the structural
and pathway facts, side by side.
NMN
NAD+ precursor · nucleotide form
NR
NAD+ precursor · nucleoside form
II
The pathway logic —
why position in the pathway matters.
The most important structural fact about NMN and NR is not their size or their charge — it is where each one enters the Salvage Pathway relative to NAMPT, the rate-limiting enzyme whose age-related decline is the primary driver of the NAD+ deficit documented in aging tissue.
NMN sits immediately downstream of NAMPT. It is what NAMPT produces. When the body makes NMN through the Salvage Pathway, it does so by NAMPT converting nicotinamide to NMN — and the rate at which this conversion happens determines how much NMN is available to NMNAT for conversion to NAD+. NMN supplementation therefore bypasses NAMPT entirely: it delivers to the pathway the molecule that NAMPT normally produces, at the step immediately before NAD+ synthesis. Whether NMN arrives at this position intact or via dephosphorylation to NR and rephosphorylation back to NMN, the net effect is precursor delivery downstream of NAMPT.
NR enters the pathway at a different point — one step further upstream. NR is converted to NMN by NRK (nicotinamide riboside kinase), and NMN is then converted to NAD+ by NMNAT. NR also bypasses NAMPT, but its route to NMN requires an additional enzymatic step — the NRK-catalyzed phosphorylation that NMN does not need. This means NR's conversion to NAD+ depends on both NRK activity and NMNAT activity, while NMN's conversion to NAD+ depends only on NMNAT. Whether this one-step difference has meaningful practical consequences depends on factors — including NRK expression levels across different tissues, the efficiency of NMN cellular uptake, and individual pharmacokinetics — that the current literature addresses only partially.
The Pathway Side by Side
How each molecule travels
through the Salvage Pathway to NAD+.
NMN · Entry Point
NMN enters the pathway
NMN is the direct product of NAMPT — the rate-limiting enzyme of the Salvage Pathway. Supplemental NMN bypasses this step, delivering the molecule at the point where NAMPT's declining activity in aging tissue would normally create a bottleneck.
NR · Entry Point
NR enters the pathway one step upstream
NR enters at the NR → NMN step, requiring NRK (nicotinamide riboside kinase) to phosphorylate it before it can proceed to NMNAT-catalyzed NAD+ synthesis. NR also bypasses NAMPT — it simply arrives at the pathway through a different enzymatic route.
NMN · Step 1
NMNAT converts NMN → NAD+
The single enzymatic step required: NMNAT (nicotinamide mononucleotide adenylyltransferase) adds an AMP group to NMN, producing NAD+. Three NMNAT isoforms exist — NMNAT1 (nuclear), NMNAT2 (cytoplasmic/Golgi), NMNAT3 (mitochondrial) — each maintaining the NAD+ pool in its respective cellular compartment.
NR · Step 1
NRK converts NR → NMN
NRK1 and NRK2 (nicotinamide riboside kinases) phosphorylate NR, adding the phosphate group that NMN already carries. This produces NMN — which then proceeds to the same NMNAT-catalyzed step that NMN-sourced precursor also requires. NRK expression varies across tissues.
NMN · Destination
NAD+ in the relevant compartment
NAD+ produced by NMNAT is available to the nuclear, cytoplasmic, or mitochondrial pools depending on which NMNAT isoform is operating. The NAD+ pool then supports sirtuin activity, PARP-mediated DNA repair, and the redox cycling of the electron transport chain.
NR · Step 2 → Destination
NMNAT converts NMN → NAD+
Once NR has been converted to NMN by NRK, the pathway is identical to NMN's route: NMNAT produces NAD+ from NMN. The same three NMNAT isoforms operate in the same compartments. From NMN onward, the two precursors are indistinguishable in terms of pathway chemistry.
What the Literature Addresses
Four dimensions where NMN and NR
have been compared in the research literature.
These comparisons are drawn from the published research literature. All studies were conducted independently and did not involve any specific Codeage product. None of what follows constitutes a claim about the superiority of either molecule over the other.
Both NMN and NR have been shown in human studies to raise blood NAD+ levels after oral supplementation. The pharmacokinetic profile of each molecule — including absorption, plasma appearance, and the relationship between circulating levels and tissue NAD+ — continues to be characterized. The clinical significance of any kinetic differences for tissue-level NAD+ in humans is still being established. Direct head-to-head pharmacokinetic comparisons between the two molecules in humans are limited, and broad conclusions about comparative kinetics are not well-supported by the current literature. Studies were conducted independently and did not involve any specific Codeage product.
Whether NMN and NR reach the same tissues with the same efficiency is a question that the current literature does not answer definitively. Animal studies suggest both molecules reach multiple tissues and raise NAD+ levels systemically, though tissue distribution patterns may differ. The specific NMNAT isoform distribution across tissues — and therefore which cellular compartments benefit most from each precursor — is an area where the science continues to develop. Claims that either molecule preferentially reaches specific tissues in humans are not yet supported by robust human data.
Both NMN and NR have been characterized as well-tolerated in human studies at the doses typically used, with multiple studies reporting no significant adverse effects across the dose ranges examined. Neither molecule should be taken without consideration of individual health status, and anyone with specific health conditions should consult a healthcare professional before supplementing with either. The safety characterization of both precursors continues to be refined as the human research base develops.
The clinical literature on functional outcomes — what NAD+ precursors actually do for measurable health parameters in humans beyond raising NAD+ levels — is still developing for both molecules. Human studies examining specific functional endpoints in various populations have been published for both NMN and NR, with parameters including muscle function, cardiovascular markers, and metabolic measures in older adults. This is an active and expanding area of research, and what is known today will continue to be refined as new findings accumulate.
The Relationship in Numbers
What the NMN–NR relationship
looks like structurally.
1
Phosphate group — the single structural difference between NMN (nucleotide) and NR (nucleoside)
The entire difference between NMN and NR is one phosphate group attached to the ribose sugar. NMN has it; NR does not. This single structural difference determines their molecular weight difference (334 vs 255 g/mol), their membrane permeability characteristics, their cellular entry mechanisms, and their respective pathway entry points. It is a meaningful difference at the molecular level — but not the categorical distinction that consumer comparisons often imply. Both molecules are on a pathway to the same destination through closely related routes.
NRK
The enzyme that defines NR's distinct entry point — converting NR to NMN before NMNAT completes the pathway to NAD+
NRK (nicotinamide riboside kinase) is the enzymatic feature that distinguishes NR's pathway entry from NMN's. NR is phosphorylated by NRK to produce NMN, which then proceeds to the NMNAT step shared by both precursors. NMN enters at the NMNAT step directly. Both routes bypass NAMPT — the rate-limiting enzyme of the Salvage Pathway — and both converge on the same NMNAT-catalyzed NAD+ synthesis. The practical significance of this structural difference in human tissue — including how NRK expression levels across different tissues affect NR's conversion efficiency — continues to be characterized in the research literature.
2
Routes to NAD+ — both NMN and NR arrive at the same Salvage Pathway destination through closely related enzymatic paths
Both NMN and NR are well-characterized NAD+ precursors that travel the Salvage Pathway to NAD+. NMN arrives at the NMNAT step directly. NR arrives via NRK phosphorylation to NMN, then NMNAT. From the NMN stage onward, the pathway chemistry is identical for both. Both bypass NAMPT — the rate-limiting enzyme whose age-related decline is central to the NAD+ depletion story — making both molecules relevant to the same underlying biological question of how to support the NAD+ pool as the Salvage Pathway's capacity changes with age.
III
What the comparison
actually resolves — and what it doesn't.
The structural biology of NMN and NR is clear: they are sequential members of the same pathway, separated by one enzymatic step and one phosphate group. The pathway logic is clear: both bypass NAMPT, both converge on NMNAT, and from NMN onward their chemistry is identical. Both molecules are well-characterized, well-tolerated routes to NAD+ precursor support — distinct in structure but united in destination. Understanding that relationship precisely, rather than framing it as a competition, is the more useful lens for anyone seeking to understand the NAD+ precursor landscape.
The question of how NMN enters cells — whether directly via a specific transporter or via conversion to NR and reconversion — remains an active area of research that may eventually produce clearer guidance on the pharmacokinetics of each molecule. Until that research matures, the most accurate statement is that both molecules represent well-characterized, well-tolerated routes to NAD+ precursor support through closely related biochemical pathways, with distinct structural properties whose practical significance in human biology continues to be studied. The biology of NMN, NR, and NAD+ precursor pharmacokinetics is a developing field, and what is described here reflects the current evidence — which will be updated as new findings accumulate.
For the broader NAD+ precursor landscape — including where NMN and NR sit among all precursors in the full family — the NAD+ precursor family article covers all four pathways to NAD+ in full context. For the NAMPT biology that gives NMN's position downstream of the rate-limiting step its significance, the NAMPT article covers the rate-limiting enzyme in depth. Both connect to Cellular Longevity — Pillar 03 of The Longevity Code.
The most accurate statement
the evidence supports:
two well-characterized routes
to NAD+ support through
closely related pathways —
whose practical differences
are still being characterized.
Codeage · Pillar 03 · Cellular Longevity
Built for the
cellular long game.
Cellular Longevity is Pillar 03 of The Longevity Code — the dimension of the system built around NAD+ biology, mitochondrial health, and the science of cellular aging.
Explore Cellular Longevity →
